Immunic, Inc. said the US Patent and Trademark Office has given it a notice of allowance for patent application 17/992,162 entitled entitled 'Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases'.
The patent covers dosing regimens associated with the company’s lead asset, vidofludimus calcium and other salt forms as well as free acid forms for the treatment of multiple sclerosis, providing protection into 2038. An additional extension, if granted, may offer up to 14 years of market exclusivity in the US on the drug's potential approval.
The patent was previously granted to the company in Japan and certain other countries.
"Coming on the heels of the recently granted dose strength patent for vidofludimus and its salts for the treatment of RMS, granting of this next fundamental patent in the United States, Japan and other countries is a critical achievement and helps to significantly strengthen the multiple layers of protection we have built around vidofludimus calcium," Daniel Vitt, Ph.D., chief executive officer and president of Immunic said in a statement.
"This patent for dosing regimens in MS patients covers all salt and free acid forms of vidofludimus and links the expected label with respective patent claims. Going forward, we expect to continue to expand the layers of patent protection around vidofludimus calcium, in order to extend the exclusivity period upon its potential regulatory approval."
Vidofludimus calcium is a small molecule investigational drug in development as an oral next-generation treatment option for patients with multiple sclerosis (MS) and other chronic inflammatory and autoimmune diseases.
Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.